Becton Dickinson Gross Margin 2010-2023 | BDX
Current and historical gross margin for Becton Dickinson (BDX) over the last 10 years. The current gross profit margin for Becton Dickinson as of December 31, 2023 is %.
| Becton Dickinson Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2023-12-31 |
$19.49B |
$8.06B |
41.37% |
| 2023-09-30 |
$19.37B |
$8.17B |
42.17% |
| 2023-06-30 |
$19.05B |
$8.55B |
44.87% |
| 2023-03-31 |
$18.81B |
$8.51B |
45.25% |
| 2022-12-31 |
$18.74B |
$8.39B |
44.78% |
| 2022-09-30 |
$18.87B |
$8.48B |
44.92% |
| 2022-06-30 |
$18.41B |
$8.10B |
43.97% |
| 2022-03-31 |
$18.38B |
$7.99B |
43.46% |
| 2021-12-31 |
$18.53B |
$8.12B |
43.81% |
| 2021-09-30 |
$19.13B |
$8.63B |
45.12% |
| 2021-06-30 |
$18.57B |
$8.36B |
45.04% |
| 2021-03-31 |
$17.82B |
$8.07B |
45.26% |
| 2020-12-31 |
$17.16B |
$7.55B |
44.00% |
| 2020-09-30 |
$16.07B |
$6.80B |
42.29% |
| 2020-06-30 |
$16.92B |
$7.64B |
45.15% |
| 2020-03-31 |
$17.41B |
$8.05B |
46.24% |
| 2019-12-31 |
$17.36B |
$8.29B |
47.78% |
| 2019-09-30 |
$17.29B |
$8.29B |
47.94% |
| 2019-06-30 |
$17.11B |
$8.12B |
47.43% |
| 2019-03-31 |
$17.04B |
$8.06B |
47.29% |
| 2018-12-31 |
$17.06B |
$7.69B |
45.06% |
| 2018-09-30 |
$15.98B |
$7.27B |
45.48% |
| 2018-06-30 |
$14.75B |
$6.75B |
45.79% |
| 2018-03-31 |
$13.50B |
$6.24B |
46.21% |
| 2017-12-31 |
$12.25B |
$6.07B |
49.51% |
| 2017-09-30 |
$12.09B |
$5.97B |
49.33% |
| 2017-06-30 |
$12.16B |
$5.94B |
48.86% |
| 2017-03-31 |
$12.32B |
$5.98B |
48.57% |
| 2016-12-31 |
$12.42B |
$6.04B |
48.59% |
| 2016-09-30 |
$12.48B |
$5.99B |
47.99% |
| 2016-06-30 |
$12.31B |
$5.87B |
47.66% |
| 2016-03-31 |
$12.23B |
$5.50B |
44.92% |
| 2015-12-31 |
$11.22B |
$5.06B |
45.09% |
| 2015-09-30 |
$10.28B |
$4.70B |
45.66% |
| 2015-06-30 |
$9.42B |
$4.37B |
46.34% |
| 2015-03-31 |
$8.46B |
$4.30B |
50.87% |
| 2014-12-31 |
$8.48B |
$4.31B |
50.83% |
| 2014-09-30 |
$8.45B |
$4.30B |
50.92% |
| 2014-06-30 |
$8.35B |
$4.29B |
51.36% |
| 2014-03-31 |
$8.24B |
$4.24B |
51.39% |
| 2013-12-31 |
$8.17B |
$4.20B |
51.41% |
| 2013-09-30 |
$8.05B |
$4.17B |
51.79% |
| 2013-06-30 |
$7.92B |
$4.09B |
51.58% |
| 2013-03-31 |
$7.85B |
$4.06B |
51.71% |
| 2012-12-31 |
$7.78B |
$4.03B |
51.79% |
| 2012-09-30 |
$7.71B |
$3.95B |
51.28% |
| 2012-06-30 |
$7.61B |
$3.90B |
51.30% |
| 2012-03-31 |
$7.58B |
$3.90B |
51.44% |
| 2011-12-31 |
$7.57B |
$3.91B |
51.66% |
| 2011-09-30 |
$7.58B |
$3.96B |
52.20% |
| 2011-06-30 |
$7.34B |
$3.85B |
52.39% |
| 2011-03-31 |
$7.22B |
$3.76B |
52.13% |
| 2010-12-31 |
$7.10B |
$3.70B |
52.11% |
| 2010-09-30 |
$7.12B |
$3.70B |
51.87% |
| 2010-06-30 |
$7.22B |
$3.75B |
51.97% |
| 2010-03-31 |
$7.21B |
$3.77B |
52.23% |
| 2009-12-31 |
$7.14B |
$3.73B |
52.23% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$67.358B |
$19.372B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
